News & Updates
Filter by Specialty:
Long-term TAF works against resistant HBV, poses no excess cardiovascular risk
17 Nov 2021
byJairia Dela Cruz
Tenofovir alafenamide (TAF) shows sustained safety and efficacy in heavily pretreated patients with multidrug-resistant hepatitis B virus (HBV) through 3 years of treatment, albeit leading to elevations in cholesterol levels.
Long-term TAF works against resistant HBV, poses no excess cardiovascular risk
17 Nov 2021TiNO-coated stent maintains edge over drug-eluting stent for ACS
16 Nov 2021
byAudrey Abella
The 3-year outcomes of the TIDES-ACS* trial continued to reflect favourable outcomes with the titanium-nitride-oxide (TiNO)-coated bioactive stent compared with a platinum-chromium-based biodegradable-polymer everolimus-eluting stent (EES) for patients with acute coronary syndrome (ACS).
TiNO-coated stent maintains edge over drug-eluting stent for ACS
16 Nov 2021Statin confers cardioprotection, survival benefit for middle-aged, older diabetics
14 Nov 2021
Statin reduces the risk of cardiovascular disease and mortality in type 2 diabetes, and this beneficial effect is evident among middle-aged and, to a lesser extent, older patients but not among young patients, a study has found.